The products are designed to deliver two Anti-Retroviral (ARV) drugs together in recommended strengths and simplify delivery of a more accurate treatment to children in resource poor settings. Both the approved formulations are reported to be scored dispersible tablets, and are pleasantly flavored.
While Coviro-LS kid contains Lamivudine 20mg and Stavudine 5mg, Coviro-LS kid DS contains the drugs in 40mg and 10mg strengths respectively. The products are bio-equivalent with the individual liquid formulations of the originators. The products are indicated for treatment of HIV infection in children.
Malvinder Mohan Singh, CEO and managing Director of Ranbaxy, said: “Ranbaxy is committed to develop innovative ARVs at affordable cost.”